Exhibit C - PREVENT Data Sharing Plan

Data relating to the primary vaccine effectiveness objective of the project will be sent to the CDC COVID-19 Vaccine Task Force investigators for pooling with results from data generated from other participating networks and analysis. No findings related to the primary vaccine effectiveness objective may be published, presented, or released by any party without approval from the CDC COVID-19 Vaccine Task Force investigators. The primary objective of this project is to evaluate SARS-CoV-2 vaccine effectiveness in preventing laboratory-confirmed symptomatic COVID-19 among HCP, including the effect of vaccine boosters and temporal changes in vaccine effectiveness.

Final de-identified project data relating to secondary or additional objectives may be shared with interested parties affiliated with research organizations, local and state health departments, universities, and other parties who are interested in using the data for public health surveillance purposes.

Interested parties must submit a description of how they plan to use de-identified data to the Project PREVENT Publication and Presentation Committee. A data-sharing agreement will be required containing conditions for data use, including: (1) a commitment to using the data only for approved purposes; (2) a commitment to secure the data using appropriate computer technology; and (3) a commitment to destroy or return the data after analyses are completed. Upon approval, the appointed Data Manager will transfer the requested data (via an agreed upon secure method and format) to the requestor. All shared final project databases will not contain direct or indirect personal or site identifiers, and participants and sites will only be discernible by unique record identification numbers. A file containing a data dictionary with descriptions of all database fields will be included with the data.